Impel NeuroPharma Announces $36M Funding to Advance Novel Drug Delivery Platform
Summary
Impel NeuroPharma closed a Series C round of up to $36 million to advance its intranasal drug delivery platform. The company will use the capital to move lead products closer to FDA approval and to develop additional indications. It also plans to continue building combination products internally and through partnerships with pharmaceutical companies. The platform aims to improve biodistribution, bioavailability, and dose consistency for therapies targeting CNS disorders and migraine, Alzheimer’s, and Parkinson’s disease.
Funding
Amount
$36.0M
Total raised
Date
December 2, 2016
Announcement date
Investors
venBio, 5AM Ventures, Vivo Ventures
Lead investors
Company
impelnp.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected